fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Budesonide

All products: Limited Use (codes 260, 261, 262, 263, 264)

Taro-Budesonide · DIN 02494280 · 0.5 mg/mL · Inh suspension

Limited Use, Reason for Use code 260, 261, 262, 263, 264 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 260, 261, 262, 263, 264 required
Write on scriptone applicable Reason for Use code, 260 or 261 or 262 or 263 or 264 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 260, 261, 262, 263, 264
Coverage limit: For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler. Reason for Use code 260 Children aged 6 years or less; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 261 Patients who have a tracheostomy; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 262 Patients with cystic fibrosis in whom nebulizer therapy is indicated; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 263 Patients with severe mental or physical disabilities; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 264 Patients who have previously used nebulizer therapy within the last 12 month period. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Taro-Budesonide · DIN 02494280 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2021-07-30 Health Canada: Marketed since 2021-06-04 · brand TARO-BUDESONIDE · ATC R03BA02 BUDESONIDE · form Suspension · route Inhalation · ingredients BUDESONIDE 0.5 MG/ML · company Taro pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Taro-Budesonide: Formulary list price $0.46 per unit (the source does not state the unit; exact figure $0.4559). What the ministry pays, not the patient.

Ministry pays: $0.4559 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02494280)

Source record
DIN 02494280: Taro-Budesonide Raw flags: sec12=Y, sec3=Y Item: 680400078; group id 704; item number 1739; lccId 00107; manufacturer id TAR Source form: Inh Susp; strength: 0.5mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.4559; ministry $0.4559 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02494280 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98431
Interchangeable products
Pulmicort Nebuamp · DIN 01978926 · $0.4559 Teva-Budesonide · DIN 02465957 · $0.4559
Shortage status: active shortage (reported April 14, 2022, last updated July 14, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02494280
Shortage record checked October 6, 2026

Other products in the same Health Canada class (R03BA): coverage varies; not interchangeable

  • Beclomethasone dipropionate (Qvar): general benefit
  • Ciclesonide (Alvesco): general benefit
  • Fluticasone furoate (Arnuity Ellipta): general benefit
  • Fluticasone (Flovent HFA): general benefit
  • Mometasone furoate (Asmanex Twisthaler): general benefit
Other drugs in the same formulary class (68:04 Corticosteroids) and how they are covered

Matched class: 68:04 Corticosteroids

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, CICLESONIDE, FLUDROCORTISONE ACETATE, FLUTICASONE FUROATE, FLUTICASONE PROPIONATE, METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, MOMETASONE FUROATE, TRIAMCINOLONE ACETONIDE Some products covered without a code (check the product listing): DEXAMETHASONE, DEXAMETHASONE 21-PHOSPHATE, HYDROCORTISONE, PREDNISOLONE SODIUM PHOSPHATE, PREDNISONE 68:04 Corticosteroids

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 50mcg/Metered Dose, 100mcg/Metered Dose · Aero Inh-200 Dose Pk

CICLESONIDE

· 3 products · General benefit · strengths: 100mcg/Actuation, 200mcg/Actuation, 50mcg/Actuation · Inh-120 Dose Pk, Metered Dose Nas Sp-120 Dose Pk

FLUTICASONE FUROATE

· 2 products · General benefit · strengths: 100mcg, 200mcg · Blister Pd Inh-30 Dose Pk

FLUTICASONE PROPIONATE

· 14 products · General benefit · strengths: 50mcg/Metered Dose, 125mcg/Metered Dose, 250mcg/Metered Dose, 55mcg/Actuation, 113mcg/Actuation, 232mcg/Actuation, 250mcg/Blister, 500mcg/Blister · Inh-120 Dose Pk, Pd Inh-60 Dose Pk

MOMETASONE FUROATE

· 3 products · General benefit · strengths: 400mcg/Metered Dose, 200mcg/Metered Dose · Pd Inh-30 Dose Pk, Pd Inh-60 Dose Pk

DEXAMETHASONE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 0.5mg, 4mg · Tab

DEXAMETHASONE 21-PHOSPHATE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 4mg/mL · Inj Sol

FLUDROCORTISONE ACETATE

· 2 products · General benefit · strengths: 0.1mg · Tab

HYDROCORTISONE

· 5 products · General benefit (4), Temporary benefit (1) · strengths: 10mg, 20mg · Tab

METHYLPREDNISOLONE

· 1 products · General benefit · strengths: 4mg · Tab

METHYLPREDNISOLONE ACETATE

· 3 products · General benefit · strengths: 40mg/mL, 80mg/mL, 100mg/5mL · Inj Susp-1mL Pk, Inj Susp-5mL Pk

PREDNISOLONE SODIUM PHOSPHATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 6.7mg/5mL · O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 68:04 and 5 more
Full class listing Related classes: 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Patients with bronchial asthma:  In patients who require inhaled steroids;  In patients for whom a reduction of systemic glucocorticoids is desirable. https://pdf.hres.ca/dpd_pm/00042073.PDF PM date: November 8, 2017 Source product: PULMICORT TURBUHALER; DIN 00851752; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Taro-Budesonide · DIN 02494280 Shortage status: active shortage (reported 2022-04-14, last updated 2026-07-14); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02494280

Check this DIN again